A new once daily triple drug treatment for cystic fibrosis is set to be “immediately funded” by NHS England following recommendation from the National Institute for Health and Care Excellence (NICE).1 ...

NHS patients in England with cystic fibrosis will be among the first in Europe to access a new treatment for their condition, ...

Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- -- Prime Medicin ...

Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...

Alyftrek (vanzacaftor–tezacaftor–deutivacaftor), made by Vertex, represents the latest advance in CFTR modulator treatments that are transforming cystic fibrosis care by targeting the underlying cause ...

Latest studies show Us pharma giant Vertex's new CF wonder pill Alyftrek has shown better results than their currently ...

Individuals with cystic fibrosis or CFTR gene variants have a 3-fold higher risk of developing pancreatic cancer after 50 years of age.

Vertex Pharmaceuticals’ cystic fibrosis (CF) therapy Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) has been approved by the European Commission (EC).

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years ...

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis portfolio.